Nucleix Adds $55M To Support EpiCheck Lung Cancer Test
The new money will help the company advance its unique EpiCheck technology for detecting cancer-specific-changes to DNA called methylation.
You may also be interested in...
Cancer diagnostics company Nucleix is planning to scale up commercial activities in Europe for its bladder test Bladder EpiCheck. The Israeli firm told Medtech Insight it is currently in advanced negotiations with distributors to expand the test's commercial reach.
The Minnesota-based health care system announced the formation of Anumana Inc. to commercialize artificial intelligence-enabled algorithms and Lucem Health to curate data collected from remote monitoring devices.
In this week’s podcast, Medtech Insight managing editor Marion Webb discusses plans by the Mayo Clinic and Veterans Health Administration to position themselves as medical device makers of 3D-printing technologies. UK-based reporter Barnaby Pickering gives an overview of global market for arthroscopy and sports medicine products.